Recruitment of p300/CBP in p53-dependent signal pathways
- PMID: 9215639
- DOI: 10.1016/s0092-8674(00)80304-9
Recruitment of p300/CBP in p53-dependent signal pathways
Abstract
The products of the p53 and CBP/p300 genes have been individually implicated in control of cell growth and regulation of transcription. p53 is known to act as a positive and negative regulator of gene expression. Here we show that p53, in both wild-type and mutant conformation, forms a specific protein complex with p300. However, in its wild-type but not mutant conformation, p53 inhibits a promoter containing the DNA-binding sequences for the transcription factor AP1, in a p300-dependent manner. p300 stimulates the transcriptional activity of p53 on p53-regulated promoters, and it enhances the responsiveness to a physiological upstream modulator of p53 function, ionizing radiation. A dominant negative form of p300 prevents transcriptional activation by p53, and it counteracts p53-mediated G1 arrest and apoptosis. The data implicate p300 as an important component of p53-signaling, thus providing new insight into the mechanisms of cellular proliferation.
Similar articles
-
Binding and modulation of p53 by p300/CBP coactivators.Nature. 1997 Jun 19;387(6635):823-7. doi: 10.1038/42981. Nature. 1997. PMID: 9194565
-
Functional interplay between p53 and E2F through co-activator p300.Oncogene. 1998 May 28;16(21):2695-710. doi: 10.1038/sj.onc.1201818. Oncogene. 1998. PMID: 9652736
-
CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein.Cancer Res. 1997 Sep 1;57(17):3693-6. Cancer Res. 1997. PMID: 9288775
-
p300/CBP/p53 interaction and regulation of the p53 response.Eur J Biochem. 2001 May;268(10):2773-8. doi: 10.1046/j.1432-1327.2001.02226.x. Eur J Biochem. 2001. PMID: 11358491 Review.
-
p300 and CBP: partners for life and death.J Cell Physiol. 1999 Nov;181(2):218-30. doi: 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5. J Cell Physiol. 1999. PMID: 10497301 Review.
Cited by
-
Targeting CBP and p300: Emerging Anticancer Agents.Molecules. 2024 Sep 24;29(19):4524. doi: 10.3390/molecules29194524. Molecules. 2024. PMID: 39407454 Free PMC article. Review.
-
Canonical and non-canonical functions of p53 isoforms: potentiating the complexity of tumor development and therapy resistance.Cell Death Dis. 2024 Jun 12;15(6):412. doi: 10.1038/s41419-024-06783-7. Cell Death Dis. 2024. PMID: 38866752 Free PMC article. Review.
-
Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy.Cancer Commun (Lond). 2024 Mar;44(3):297-360. doi: 10.1002/cac2.12520. Epub 2024 Feb 4. Cancer Commun (Lond). 2024. PMID: 38311377 Free PMC article. Review.
-
VprBP/DCAF1 regulates p53 function and stability through site-specific phosphorylation.Oncogene. 2023 Apr;42(17):1405-1416. doi: 10.1038/s41388-023-02685-8. Epub 2023 Apr 11. Oncogene. 2023. PMID: 37041410 Free PMC article.
-
Effects of the Acetyltransferase p300 on Tumour Regulation from the Novel Perspective of Posttranslational Protein Modification.Biomolecules. 2023 Feb 22;13(3):417. doi: 10.3390/biom13030417. Biomolecules. 2023. PMID: 36979352 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous
